| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
49,340,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$ - $ |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile 4D Molecular Therapeutics is a clinical-stage gene therapy company engaging the development of product candidates using its targeted and evolved adeno-associated viruses vectors. Co. has built a portfolio of gene therapy product candidates, with five product candidates in clinical trials: 4D-125 for the treatment of X-linked retinitis pigmentosa, 4D-150 for the treatment of wet age-related macular degeneration, 4D-110 for the treatment of choroideremia, 4D-310 for the treatment of Fabry disease, and 4D-710 for the treatment of cystic fibrosis lung disease.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
850,000 |
850,000 |
| Total Buy Value |
$0 |
$0 |
$13,600,000 |
$13,600,000 |
| Total People Bought |
0 |
0 |
1 |
1 |
| Total Buy Transactions |
0 |
0 |
1 |
1 |
| Total Shares Sold |
143,942 |
791,941 |
797,938 |
955,783 |
| Total Sell Value |
$4,074,293 |
$16,684,699 |
$16,804,030 |
$20,280,103 |
| Total People Sold |
3 |
4 |
4 |
5 |
| Total Sell Transactions |
9 |
15 |
17 |
27 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Bizily Scott |
Chief Legal Officer |
• – – |
2024-04-16 |
4 |
AS |
$25.74 |
$45,045 |
D/D |
(1,750) |
1,737 |
|
- |
|
| Bizily Scott |
Chief Legal Officer |
• – – |
2024-04-16 |
4 |
OE |
$6.49 |
$13,295 |
D/D |
1,750 |
3,487 |
|
- |
|
| Bizily Scott |
Chief Legal Officer |
• – – |
2024-04-01 |
4 |
AS |
$31.78 |
$259,102 |
D/D |
(8,153) |
1,737 |
|
- |
|
| Bizily Scott |
Chief Legal Officer |
• – – |
2024-04-01 |
4 |
OE |
$6.49 |
$102,224 |
D/D |
8,153 |
9,890 |
|
- |
|
| Bizily Scott |
Chief Legal Officer |
• – – |
2024-03-27 |
4 |
AS |
$35.04 |
$204,410 |
D/D |
(5,833) |
1,737 |
|
- |
|
| Bizily Scott |
Chief Legal Officer |
• – – |
2024-03-27 |
4 |
OE |
$25.98 |
$151,541 |
D/D |
5,833 |
7,570 |
|
- |
|
| Bizily Scott |
Chief Legal Officer |
• – – |
2024-03-18 |
4 |
AS |
$31.27 |
$54,723 |
D/D |
(1,750) |
1,737 |
|
- |
|
| Bizily Scott |
Chief Legal Officer |
• – – |
2024-03-18 |
4 |
OE |
$6.49 |
$13,295 |
D/D |
1,750 |
3,487 |
|
- |
|
| Bizily Scott |
Chief Legal Officer |
• – – |
2024-02-27 |
4 |
AS |
$30.00 |
$57,270 |
D/D |
(1,909) |
1,737 |
|
- |
|
| Bizily Scott |
Chief Legal Officer |
• – – |
2024-02-27 |
4 |
OE |
$20.24 |
$38,638 |
D/D |
1,909 |
3,646 |
|
- |
|
| Bizily Scott |
Chief Legal Officer |
• – – |
2024-02-16 |
4 |
AS |
$27.67 |
$48,423 |
D/D |
(1,750) |
1,737 |
|
- |
|
| Bizily Scott |
Chief Legal Officer |
• – – |
2024-02-16 |
4 |
OE |
$6.49 |
$13,295 |
D/D |
1,750 |
3,487 |
|
- |
|
| Bizily Scott |
Chief Legal Officer |
• – – |
2024-02-08 |
4 |
AS |
$27.50 |
$171,710 |
D/D |
(6,244) |
1,737 |
|
- |
|
| Bizily Scott |
Chief Legal Officer |
• – – |
2024-02-08 |
4 |
OE |
$6.49 |
$63,586 |
D/D |
6,244 |
3,733 |
|
- |
|
| Kirn David |
Chief Executive Officer |
• • – |
2024-02-08 |
4 |
AS |
$27.13 |
$2,495,822 |
D/D |
(92,001) |
1,059,153 |
|
- |
|
| Kim Robert Young |
Chief Medical Officer |
• – – |
2024-02-07 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
1,595 |
|
- |
|
| Kim Robert Young |
Chief Medical Officer |
• – – |
2024-02-05 |
4 |
AS |
$30.05 |
$737,788 |
D/D |
(24,552) |
1,043 |
|
- |
|
| Kim Robert Young |
Chief Medical Officer |
• – – |
2024-02-05 |
4 |
OE |
$8.04 |
$366,840 |
D/D |
24,000 |
7,595 |
|
- |
|
| Kirn David |
Chief Executive Officer |
• • – |
2024-01-23 |
4 |
AS |
$18.41 |
$104,851 |
D/D |
(5,696) |
1,151,154 |
|
- |
|
| Kirn David |
Chief Executive Officer |
• • – |
2024-01-05 |
4 |
AS |
$19.56 |
$552,478 |
D/D |
(28,237) |
1,156,850 |
|
- |
|
| Kirn David |
Chief Executive Officer |
• • – |
2024-01-04 |
4 |
AS |
$20.31 |
$827,202 |
D/D |
(40,732) |
1,185,087 |
|
- |
|
| Shabet Rose Sharon |
|
• • • |
2024-01-04 |
4 |
S |
$19.53 |
$10,546,200 |
I/I |
(540,000) |
4,247,914 |
|
- |
|
| Kirn David |
Chief Executive Officer |
• • – |
2023-12-18 |
4 |
AS |
$18.13 |
$85,243 |
D/D |
(4,702) |
1,225,819 |
|
- |
|
| Kirn David |
Chief Executive Officer |
• • – |
2023-12-15 |
4 |
AS |
$17.27 |
$494,432 |
D/D |
(28,632) |
1,230,521 |
|
- |
|
| Bizily Scott |
Chief Legal and HR Officer |
• • – |
2023-06-08 |
4 |
AS |
$20.85 |
$78,188 |
D/D |
(3,750) |
1,737 |
|
- |
|
66 Records found
|
|
Page 1 of 3 |
|
|
